Predictors and changes of physical activity in idiopathic pulmonary fibrosis.

Depression Idiopathic pulmonary fibrosis Muscle strength Physical activity Predictors Prognosis

Journal

BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563

Informations de publication

Date de publication:
09 Sep 2022
Historique:
received: 03 05 2022
accepted: 22 08 2022
entrez: 9 9 2022
pubmed: 10 9 2022
medline: 14 9 2022
Statut: epublish

Résumé

Different clinical predictors of physical activity (PA) have been described in idiopathic pulmonary fibrosis (IPF), but studies are lacking evaluating the potential role of muscle strength and anxiety and depression symptoms in PA limitation. Moreover, little is known about the impact of changes in PA in the course of the disease. The aim of the present study was to investigate the relationship between baseline PA and a wide range of variables in IPF, to assess its longitudinal changes at 12 months and its impact on progression free-survival. PA was assessed by accelerometer and physiological, clinical, psychological factors and health-related quality of life were evaluated in subjects with IPF at baseline and at 12 month follow-up. Predictors of PA were determined at baseline, evolution of PA parameters was described and the prognostic role of PA evolution was also established. Forty participants with IPF were included and 22 completed the follow-up. At baseline, subjects performed 5765 (3442) daily steps and spent 64 (44) minutes/day in moderate to vigorous PA. Multivariate regression models showed that at baseline, a lower six-minute walked distance, lower quadriceps strength (QMVC), and a higher depression score in the Hospital Anxiety and Depression scale were associated to lower daily step number. In addition, being in (Gender-Age-Physiology) GAP III stage, having a BMI ≥ 25 kg/m Among a wide range of variables, muscle strength and depression symptoms have a predominant role in PA in IPF patients. Daily PA behaviour and its evolution should be considered in IPF clinical assessment and as a potential complementary indicator of disease prognosis.

Sections du résumé

BACKGROUND BACKGROUND
Different clinical predictors of physical activity (PA) have been described in idiopathic pulmonary fibrosis (IPF), but studies are lacking evaluating the potential role of muscle strength and anxiety and depression symptoms in PA limitation. Moreover, little is known about the impact of changes in PA in the course of the disease. The aim of the present study was to investigate the relationship between baseline PA and a wide range of variables in IPF, to assess its longitudinal changes at 12 months and its impact on progression free-survival.
METHODS METHODS
PA was assessed by accelerometer and physiological, clinical, psychological factors and health-related quality of life were evaluated in subjects with IPF at baseline and at 12 month follow-up. Predictors of PA were determined at baseline, evolution of PA parameters was described and the prognostic role of PA evolution was also established.
RESULTS RESULTS
Forty participants with IPF were included and 22 completed the follow-up. At baseline, subjects performed 5765 (3442) daily steps and spent 64 (44) minutes/day in moderate to vigorous PA. Multivariate regression models showed that at baseline, a lower six-minute walked distance, lower quadriceps strength (QMVC), and a higher depression score in the Hospital Anxiety and Depression scale were associated to lower daily step number. In addition, being in (Gender-Age-Physiology) GAP III stage, having a BMI ≥ 25 kg/m
CONCLUSION CONCLUSIONS
Among a wide range of variables, muscle strength and depression symptoms have a predominant role in PA in IPF patients. Daily PA behaviour and its evolution should be considered in IPF clinical assessment and as a potential complementary indicator of disease prognosis.

Identifiants

pubmed: 36085057
doi: 10.1186/s12890-022-02134-4
pii: 10.1186/s12890-022-02134-4
pmc: PMC9461180
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

340

Subventions

Organisme : Instituto de Salud Carlos III
ID : Rio Hortega

Informations de copyright

© 2022. The Author(s).

Références

Eur Respir J. 2009 Feb;33(2):262-72
pubmed: 19010994
Multidiscip Respir Med. 2010 Jun 30;5(3):211-5
pubmed: 22958444
Lung. 2019 Feb;197(1):37-45
pubmed: 30430249
Thorax. 1999 Jul;54(7):581-6
pubmed: 10377201
Respirology. 2015 May;20(4):640-6
pubmed: 25728219
Respiration. 2016;91(6):497-502
pubmed: 27240427
BMC Pulm Med. 2019 Oct 21;19(1):183
pubmed: 31638951
BMJ Open Respir Res. 2017 Sep 17;4(1):e000212
pubmed: 29018526
Respir Med. 2019 May;151:81-95
pubmed: 31047122
Chron Respir Dis. 2016 May;13(2):162-72
pubmed: 26768011
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Eur Respir Rev. 2018 Dec 21;27(150):
pubmed: 30578335
Thorax. 1980 Feb;35(2):92-100
pubmed: 7376125
Respiration. 2021;100(12):1151-1157
pubmed: 34247176
Lung. 2019 Aug;197(4):415-425
pubmed: 31154459
Chest. 2005 Jun;127(6):2028-33
pubmed: 15947316
Int J Chron Obstruct Pulmon Dis. 2016 Jun 10;11:1287-95
pubmed: 27354787
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Eur Respir J. 2005 Oct;26(4):720-35
pubmed: 16204605
Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
pubmed: 1759018
Respirology. 2021 Dec;26(12):1152-1159
pubmed: 34448321
Clin Nutr. 2005 Apr;24(2):250-8
pubmed: 15784486
Respir Res. 2019 Mar 12;20(1):56
pubmed: 30866948
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Clin Chest Med. 2019 Jun;40(2):405-420
pubmed: 31078218
BMC Pulm Med. 2017 Jul 25;17(1):104
pubmed: 28743305
Chest. 2011 Aug;140(2):331-342
pubmed: 21273294
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
Respir Investig. 2018 Jan;56(1):57-63
pubmed: 29325683
Am J Respir Crit Care Med. 1996 Mar;153(3):976-80
pubmed: 8630582
J Cardiopulm Rehabil Prev. 2011 Jan-Feb;31(1):11-24
pubmed: 20724932
J Appl Physiol (1985). 2013 May;114(9):1222-34
pubmed: 23519228
Arch Bronconeumol. 1997 May;33(5):213-9
pubmed: 9254166
Med Sci Sports Exerc. 2007 Aug;39(8):1423-34
pubmed: 17762377
Chest. 2013 Nov;144(5):1652-1658
pubmed: 23928896

Auteurs

Diana Badenes-Bonet (D)

Interstitial Lung Disease Unit, Respiratory Medicine Department, Hospital del Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Anna Rodó-Pin (A)

Interstitial Lung Disease Unit, Respiratory Medicine Department, Hospital del Mar, Passeig Marítim 25, 08003, Barcelona, Spain.

Diego Castillo-Villegas (D)

Respiratory Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Vanesa Vicens-Zygmunt (V)

Respiratory Medicine Department, IDIBELL, Hospital Universitari de Bellvitge, Barcelona, Spain.

Guadalupe Bermudo (G)

Respiratory Medicine Department, IDIBELL, Hospital Universitari de Bellvitge, Barcelona, Spain.

Fernanda Hernández-González (F)

Respiratory Medicine Department, Hospital Clínic, Barcelona, Spain.

Karina Portillo (K)

Respiratory Medicine Department, Hospital Germans Trias i Pujol, Barcelona, Spain.

Juana Martínez-Llorens (J)

Interstitial Lung Disease Unit, Respiratory Medicine Department, Hospital del Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Centro de Investigación en Red de Enfermedades Respiratorias, (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Roberto Chalela (R)

Interstitial Lung Disease Unit, Respiratory Medicine Department, Hospital del Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Oswaldo Caguana (O)

Interstitial Lung Disease Unit, Respiratory Medicine Department, Hospital del Mar, Passeig Marítim 25, 08003, Barcelona, Spain.

Jacobo Sellarés (J)

Respiratory Medicine Department, Hospital Clínic, Barcelona, Spain.

Maria Molina-Molina (M)

Centro de Investigación en Red de Enfermedades Respiratorias, (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Respiratory Medicine Department, IDIBELL, Hospital Universitari de Bellvitge, Barcelona, Spain.

Xavier Duran (X)

Scientific, Statistics and Technical Department, Hospital del Mar-IMIM, Barcelona, Spain.

Joaquim Gea (J)

Interstitial Lung Disease Unit, Respiratory Medicine Department, Hospital del Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Centro de Investigación en Red de Enfermedades Respiratorias, (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Diego Agustín Rodríguez-Chiaradia (DA)

Interstitial Lung Disease Unit, Respiratory Medicine Department, Hospital del Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Centro de Investigación en Red de Enfermedades Respiratorias, (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Eva Balcells (E)

Interstitial Lung Disease Unit, Respiratory Medicine Department, Hospital del Mar, Passeig Marítim 25, 08003, Barcelona, Spain. ebalcells@psmar.cat.
Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain. ebalcells@psmar.cat.
Centro de Investigación en Red de Enfermedades Respiratorias, (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain. ebalcells@psmar.cat.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. ebalcells@psmar.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH